➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Mallinckrodt
AstraZeneca
McKesson
Colorcon

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

Litigation Details for CELGENE CORPORATION v. SYNTHON PHARMECEUTICALS, INC. (D.N.J. 2018)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

CELGENE CORPORATION v. SYNTHON PHARMECEUTICALS, INC. (D.N.J. 2018)

Docket   Start Trial Date Filed 2018-06-19
Court District Court, D. New Jersey Date Terminated 2019-05-13
Cause 15:1126 Patent Infringement Assigned To Esther Salas
Jury Demand None Referred To Michael A. Hammer
Parties ALVOGEN PINE BROOK, LLC; CELGENE CORPORATION; SYNTHON B.V.; SYNTHON PHARMECEUTICALS, INC.; SYNTHON S.R.O.
Patents 4,810,643; 4,999,291; 5,134,127; 5,580,755; 5,629,327; 5,635,517; 6,020,358; 6,235,756; 6,281,230; 6,316,471; 6,476,052; 6,555,554; 7,393,862; 7,435,745; 7,968,569; 8,198,262; 8,673,939; 8,735,428; 8,828,427; 9,993,467
Attorneys AARON SCOTT ECKENTHAL; BRIAN JOHN FORSATZ; CHARLES MICHAEL LIZZA; DAVID LEIGH MOSES; FRANK CHARLES CALVOSA; PAUL HILGER KOCHANSKI; SARAH ANN SULLIVAN; TEDD WILLIAM VAN BUSKIRK; WILLIAM C. BATON
Firms Lerner David Littenberg Krumholz and Mentlik LLP; Lerner, David, Littenberg, Krumholz & Mentlik, LLP; Quinn Emanuel Uquhart & Sullival LLP; Quinn Emanuel Urquhart & Sullivan LLC; Saul Ewing Arnstein & Lehr LLP
Link to Docket External link to docket
Small Molecule Drugs cited in CELGENE CORPORATION v. SYNTHON PHARMECEUTICALS, INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in CELGENE CORPORATION v. SYNTHON PHARMECEUTICALS, INC.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for CELGENE CORPORATION v. SYNTHON PHARMECEUTICALS, INC. (D.N.J. 2018)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 Complaint (Continued) 4,810,643 A 3/1989 Souza 4,999,291 … prepared as described in U.S. Pat. Nos. 4,810,643; 4,999,291; somer of the compound and less than… United States Patent Nos. 8,198,262 (the “’262 patent”), 8,673,939 (the “’939 patent”), 8,735,428 (the…428 patent”), and 8,828,427 (the “’427 patent”), all owned by Celgene (collectively, “the patents-in-… 1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C External link to document
0000-00-00 24 Amended Complaint (Continued) 4,810,643 A 3/1989 Souza 4,999,291 … prepared as described in U.S. Pat. Nos. 4,810,643; 4,999,291; somer of the compound and less than…claims of the ’262 patent, the ’939 patent, the ’428 patent, and the ’427 patent are invalid and/or … United States Patent Nos. 8,198,262 (the “’262 patent”), 8,673,939 (the “’939 patent”), 8,735,428 (… (the “’428 patent”), 8,828,427 (the “’427 patent”), and 9,993,467 (the “’467 patent”), all owned by External link to document
0000-00-00 50 Letter Consent Judgment, the term “Patents-in-Suit” shall mean U.S. Patent Nos. 8,198,262; 8,673,939; 8,735,428; … 4. Until expiration of the Patents-in-Suit, Synthon, including any of its successors…successors and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any third …parties in connection with any infringement of the Patents-in-Suit by any such third parties in connection… 21 C.F.R. § 314.94(a)(12) with respect to the Patents-in-Suit. 9. Nothing herein External link to document
0000-00-00 52 Consent Judgment, the term “Patents-in-Suit” shall mean U.S. Patent Nos. 8.198,262; 8,673,939; 8.735.428: …10,093,648: and 10,093,649, 4. Until expiration of the Patents-in-Suit. Synthon, including any of its successors…successors and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any third party…parties in connection with any infringement of the Patents-in-Suit by any such third parties in connection…21 C.F.R. §$ 314.94(a)(12) with respect to the Patents-in-Suit. 9, Nothing herein restricts or is intended External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Boehringer Ingelheim
Colorcon
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.